89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase...
COVID-19
Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit
WOBURN, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life...
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it...
Surrozen Reports Second Quarter 2022 Financial Results
Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoingPreclinical proof-of-concept data for multiple programs presented and published in...
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently...
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
Company maintains strong cash position of $207.3 millionSOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
OrthoPediatrics Corp. Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
WARSAW, Ind., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively...
Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement
FORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today...
Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312...
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial...
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline...
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the...
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced...
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative...
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid...
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- Topline Data Expected First Quarter 2023 -DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva...
Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test
Lucira COVID-19 & Flu Test – the 99% Accurate At-Home Test for Covid and Flu The first and only at-home...
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data...
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in...